Chronic pain affects at least 10% of the world’s population – approximately 60 million people due to the complexity of pain still lack effective treatments for many pain disorders. Doctors worldwide call for the development of novel analgesics whose mechanisms do not involve the mu (μ) receptors. Thanks to the experience, Biokinetica is armed with the knowledge to help drug developers bring novel analgesics to the market.
